Mounjaro (Tirzepatide) Mechanism of Action : Mounjaro (Tirzepatide) is a dual GIP and GLP-1 receptor agonist, while Amycretin combines GLP-1 and amylin receptor activation
It mimics three hormones: GLP-1 (the same as Wegovy), GIP (a related gut hormone that affects insulin and fat storage, the same as Mounjaro), and glucagon
These findings represent the largest pharmacologically induced liver fat reduction reported to date, with Phase 3 results anticipated in 2026
Retatrutide wins on the dimensions that matter most for frontier research: higher observed ceiling in TRIUMPH-4, triple-agonist mechanism breadth, and consistent direction across both published network meta-analyses
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
Recognising the warning signs of a more serious reaction is an important aspect of patient safety